Currently, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is one of the most promising therapeutic approaches for lowering hypercholesterolemia and reducing the incidence of atherosclerotic cardiovascular disease (ACVD), particularly in patients with familial hypercholesterolemia and those experiencing statin resistance or intolerance [1,2,3,4]. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.